The small increased risks noted in the FDA’s announcement were determined by evaluating large clinical trials such as JUPITER which showed a trend towards an increased risk of reversible cognitive impairment defined by a relative risk of 1.33.
← all excerpts
The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms.
1
—
—